42 related articles for article (PubMed ID: 22819377)
1. Potential role of oxidative stress in pathogenesis of benign prostatic hyperplasia in male dogs.
Domosławska-Wyderska A; Zduńczyk S; Rafalska A
Reprod Domest Anim; 2024 May; 59(5):e14580. PubMed ID: 38698701
[TBL] [Abstract][Full Text] [Related]
2. Intraprostatic botulinum toxin injection in patients with benign prostatic enlargement.
Ilie CP; Chancellor MB; Chuang YC; Dan M
J Med Life; 2009; 2(4):338-42. PubMed ID: 20108746
[TBL] [Abstract][Full Text] [Related]
3. Comparative Evaluation of Diagnostic Methods for Subclinical Benign Prostatic Hyperplasia in Intact Breeding Male Dogs.
Laurusevičius T; Šiugždaitė J; Juodžiukynienė N; Kerzienė S; Anskienė L; Jackutė V; Trumbeckas D; Van Soom A; Posastiuc FP; Žilinskas H
Animals (Basel); 2024 Apr; 14(8):. PubMed ID: 38672352
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Applications of Botulinum Neurotoxins in Veterinary Medicine.
Turin L; Piccione MM; Crosa F; Dall'Ara P; Filipe J; Zarucco L
Vet Sci; 2023 Jul; 10(7):. PubMed ID: 37505863
[TBL] [Abstract][Full Text] [Related]
5. Canine prostate models in preclinical studies of minimally invasive interventions: part II, benign prostatic hyperplasia models.
Sun F; Báez-Díaz C; Sánchez-Margallo FM
Transl Androl Urol; 2017 Jun; 6(3):547-555. PubMed ID: 28725598
[TBL] [Abstract][Full Text] [Related]
6. [Intraprostatic injection therapy in patients with benign prostatic syndrome].
Bschleipfer T; Bach T; Gratzke C; Madersbacher S; Oelke M
Urologe A; 2013 Mar; 52(3):354-8. PubMed ID: 23435646
[TBL] [Abstract][Full Text] [Related]
7. Botulinum neurotoxin A for benign prostatic hyperplasia.
Oeconomou A; Madersbacher H
Curr Opin Urol; 2010 Jan; 20(1):28-36. PubMed ID: 19887944
[TBL] [Abstract][Full Text] [Related]
8. The application of botulinum toxin in the prostate.
Chuang YC; Chancellor MB
J Urol; 2006 Dec; 176(6 Pt 1):2375-82. PubMed ID: 17085104
[TBL] [Abstract][Full Text] [Related]
9. Urodynamic effects of transrectal intraprostatic Ona botulinum toxin A injections for symptomatic benign prostatic hyperplasia.
de Kort LM; Kok ET; Jonges TN; Rosier PF; Bosch JL
Urology; 2012 Oct; 80(4):889-93. PubMed ID: 22854138
[TBL] [Abstract][Full Text] [Related]
10. Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function.
Silva J; Pinto R; Carvalho T; Botelho F; Silva P; Silva C; Cruz F; Dinis P
BJU Int; 2011 Jun; 107(12):1950-4. PubMed ID: 21105985
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia.
Park DS; Cho TW; Lee YK; Lee YT; Hong YK; Jang WK
Yonsei Med J; 2006 Oct; 47(5):706-14. PubMed ID: 17066515
[TBL] [Abstract][Full Text] [Related]
12. Effects of benign prostatic hyperplasia and finasteride therapy on prostatic blood flow in dogs.
Angrimani DSR; Silvestrini GR; Brito MM; Abreu RA; Almeida LL; Vannucchi CI
Theriogenology; 2018 Jul; 114():103-108. PubMed ID: 29605575
[TBL] [Abstract][Full Text] [Related]
13. Prostate botulinum A toxin injection--an alternative treatment for benign prostatic obstruction in poor surgical candidates.
Kuo HC
Urology; 2005 Apr; 65(4):670-4. PubMed ID: 15833506
[TBL] [Abstract][Full Text] [Related]
14. Intra-prostatic injection of botulinum toxin type A in treatment of dogs with spontaneous benign prostatic hyperplasia.
Mostachio GQ; Apparício M; Motheo TF; Alves AE; Vicente WR
Anim Reprod Sci; 2012 Aug; 133(3-4):224-8. PubMed ID: 22819377
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
